340B Drug Pricing Program Contributes to Rising Healthcare Costs and Is Ripe for Reform
The U.S. House Energy & Commerce Committee's Health Subcommittee today will host the third hearing in its health care affordability series, specifically examining the role providers and hospitals play in shaping the cost of care for Americans.
While the hearing will likely examine numerous issues, there is none more ripe for reform than the flawed 340B drug pricing program.
Originally enacted to help eligible safety-net providers buy medicines at steep discounts and pass the savings on to lower-income and vulnerable patients, the program has ballooned as a revenue stream for many participating hospitals and contract pharmacy chains.
As the size and complexity of the 340B program has expanded, participating hospitals and contract pharmacies have instead used the program to increase…[more]
The trial of former President Donald Trump is heading toward a conclusion. For those who at the beginning thought the case was weak and politically motivated, the presentation of the prosecution's evidence has made it seem even weaker and more politically motivated. A conviction will not change that.
On the other side, though, some in the anti-Trump world who were originally skeptical about the case's merits have come to believe that it is actually stronger than they first thought. That was not necessarily because the case is actually stronger, but because, as events unfolded, it became clear…
